石家庄以岭药业股份有限公司 关于子公司药品通过谈判纳入 《国家医保目录》的公告

Core Viewpoint - The announcement highlights that Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s subsidiary, Beijing Yiling Pharmaceutical Co., Ltd., has successfully negotiated to include its product, Qifang Bitong Pian, in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's market promotion and sales scale [1][2]. Group 1: Product Inclusion in National Medical Insurance - Qifang Bitong Pian is a proprietary product developed by the company, classified as a Class 1 traditional Chinese medicine, specifically for treating persistent allergic rhinitis [1]. - The product has been assigned a medical insurance payment standard of 1.78 yuan per tablet, with a validity period for the agreement from January 1, 2026, to December 31, 2027 [1]. - The company holds complete intellectual property rights for Qifang Bitong Pian, which received its drug registration certificate from the National Medical Products Administration in January 2025 [1]. Group 2: Impact on Company Operations - In addition to Qifang Bitong Pian, the company has 11 other proprietary products included in the National Medical Insurance Directory for 2025, which may enhance the company's market presence and sales [2]. - The inclusion of these 12 proprietary traditional Chinese medicine products in the insurance directory is expected to have a positive long-term impact on the company's operational development, although the short-term effects on financial performance are currently uncertain [2].